147 related articles for article (PubMed ID: 16542272)
1. Positive and negative predictive values: use of inflammatory bowel disease serologic markers.
Austin GL; Shaheen NJ; Sandler RS
Am J Gastroenterol; 2006 Mar; 101(3):413-6. PubMed ID: 16542272
[No Abstract] [Full Text] [Related]
2. Immunological markers anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: a helpful diagnostic tool.
Montanelli A; Mainardi E; Vagni A; Villanacci V; Zambelli C; Cestari R; Cengia P; Minelli L; Missale G
Minerva Gastroenterol Dietol; 2005 Jun; 51(2):201-7. PubMed ID: 15990710
[TBL] [Abstract][Full Text] [Related]
3. Antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies in inflammatory bowel diseases.
Kiliç ZM; Tunç B; Ayaz S; Filik L; Aktaş S; Parlak E; Ulker A
Turk J Gastroenterol; 2004 Dec; 15(4):238-42. PubMed ID: 16249978
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of serological markers in inflammatory bowel disease.
Mokrowiecka A; Daniel P; Słomka M; Majak P; Malecka-Panas E
Hepatogastroenterology; 2009; 56(89):162-6. PubMed ID: 19453050
[TBL] [Abstract][Full Text] [Related]
5. [Physiopathology of inflammatory bowel diseases: new biological tools for disease diagnosis and monitoring?].
Desreumaux P; Bourreille A; Colombel JF
Gastroenterol Clin Biol; 2003 Mar; 27(3 Suppl):S81-6. PubMed ID: 12704300
[No Abstract] [Full Text] [Related]
6. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
[TBL] [Abstract][Full Text] [Related]
7. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.
Buckland MS; Mylonaki M; Rampton D; Longhurst HJ
Clin Diagn Lab Immunol; 2005 Nov; 12(11):1328-30. PubMed ID: 16275949
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of serological assays in pediatric inflammatory bowel disorders.
Mainardi E; Villanacci V; Bassotti G; Liserre B; Rossi E; Incardona P; Falchetti D; Tonegatti L; Montanelli A; Barabino A; Coccia C; Gambini C
Digestion; 2007; 75(4):210-4. PubMed ID: 17952008
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic tools in inflammatory bowel diseases].
Bouhnik Y
Rev Prat; 2005 May; 55(9):977-83. PubMed ID: 16052968
[TBL] [Abstract][Full Text] [Related]
10. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients.
Amre DK; Lu SE; Costea F; Seidman EG
Am J Gastroenterol; 2006 Mar; 101(3):645-52. PubMed ID: 16464223
[TBL] [Abstract][Full Text] [Related]
11. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies: serologic markers in inflammatory bowel disease.
Hartman C; Eliakim R; Shamir R
Isr Med Assoc J; 2004 Apr; 6(4):221-6. PubMed ID: 15115261
[No Abstract] [Full Text] [Related]
12. [Serological markers in inflammatory bowel disease: differences among populations and limitations of their application].
Barahona-Garrido J; Hernández-Calleros J; Sarti HM; Cabiedes J; Yamamoto-Furusho JK
Gastroenterol Hepatol; 2009 May; 32(5):380-1. PubMed ID: 19457592
[No Abstract] [Full Text] [Related]
13. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
14. [Differential diagnosis of chronic inflammatory bowel diseases. Value of determination of autoantibodies pANCA, ASCA AND PAB (perinuclear antineutrophil cytoplasmic antibody, antibody against Saccharomyces cerevisiae, antibody against pancreas)].
Seibold F; Hufnagl R; Scheurlen M
Fortschr Med; 1999 Feb; 117(6):42-3. PubMed ID: 10095303
[No Abstract] [Full Text] [Related]
15. Serologic markers in inflammatory bowel disease: state of the art.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4(4):167-74. PubMed ID: 15580151
[TBL] [Abstract][Full Text] [Related]
16. Exploring life before IBD.
De Vroey B; Gower-Rousseau C; Colombel JF
Gut; 2013 May; 62(5):662-3. PubMed ID: 22936675
[No Abstract] [Full Text] [Related]
17. Differentiation of Behcet's disease from inflammatory bowel diseases: anti-Saccharomyces cerevisiae antibody and anti-neutrophilic cytoplasmic antibody.
Filik L; Biyikoglu I
World J Gastroenterol; 2008 Dec; 14(47):7271. PubMed ID: 19084948
[TBL] [Abstract][Full Text] [Related]
18. The value of serological and genetic markers in inflammatory bowel disease; strength and weakness of the studies.
Peña AS
Rev Esp Enferm Dig; 2003 Nov; 95(11):752-4, 749-51. PubMed ID: 14640872
[No Abstract] [Full Text] [Related]
19. Serologic testing in inflammatory bowel disease: its value in indeterminate colitis.
Papadakis KA; Targan SR
Curr Gastroenterol Rep; 1999 Dec; 1(6):482-5. PubMed ID: 10980990
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory Bowel Disease Serological Immune Markers Anti-Saccharomyces cerevisiae Mannan Antibodies and Outer Membrane Porin C are Potential Biomarkers for Hirschsprung-associated Enterocolitis.
Frykman PK; Patel DC; Kim S; Cheng Z; Wester T; Nordenskjöld A; Kawaguchi A; Hui TT; Ehrlich PF; Granström AL; Benliyan F;
J Pediatr Gastroenterol Nutr; 2019 Aug; 69(2):176-181. PubMed ID: 30964819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
